Changes in 18F-FDG-PET/CT tumor metabolism and prediction of pathologic complete response rates after neoadjuvant chemotherapy in hormone-positive breast cancer
| Autor: | Rahib Hasanov, Z. Ozgen, Umit Ugurlu, Suleyman Halil, Nalan Akgul Babacan, Fulden Yumuk, Faysal Dane, Eda Tanrikulu Simsek, Fuat Dede, Handan Kaya, Bilge Aktas, Mehmet Akif Ozturk, Mahmut Gumus, Ozkan Alan, Serap Kaya, Sinan Koca |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
Oncology
Cancer Research medicine.medical_specialty Chemotherapy Anthracycline business.industry medicine.medical_treatment medicine.disease Primary tumor Surgery Axilla medicine.anatomical_structure Breast cancer Trastuzumab Internal medicine medicine Breast-conserving surgery skin and connective tissue diseases business medicine.drug Hormone |
| Zdroj: | Journal of Clinical Oncology. 34:e12088-e12088 |
| ISSN: | 1527-7755 0732-183X |
| DOI: | 10.1200/jco.2016.34.15_suppl.e12088 |
| Popis: | e12088Background: Neoadjuvant chemotherapy (NAC) by reducing the tumor size provides higher operability and breast conserving surgery rate in locally advanced breast cancer (LABC) with an advantage to evaluate chemotherapy response. The aim of this study was to assess the predictive value of relative changes in standard uptake values (SUVmax) of 18F-FDG-PET/CT for pathologic complete response (pCR) after NAC in hormone-positive breast cancer. Methods: 90 hormone-positive LABC patients treated in Marmara University Pendik Research and Training Hospital Medical Oncology Clinics, Istanbul, Turkey between 2009 and 2015 was screened. Eligibility criteria were receiving histopathological verification of hormone–positive LABC, completed NAC (4-8 cycles) and evaluated for pCR postoperatively, and PET/CT scan was performed before and after NAC (anthracycline and/or taxanes-based plus trastuzumab if necessary). The relative changes of SUVmax both in primary tumor and axilla were determined and assessed for predicti... |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|